Important pharmacy news and late-breaking industry information updated daily.

In late June, science was made when Camille Schrier, PharmD candidate and APhA member, was crowned Miss Virginia 2019. Pharmacy Today was lucky to catch up with Schrier for an interview. Below is an edited version of the conversion. For the full article, please visit www.pharmacytoday.org for the August 2019 issue of Pharmacy Today.

Results of two recently published studies suggest that for patients with mild asthma, clinicians may need to rethink the current recommended treatment algorithm. The Novel START trial showed that use of budesonide-formoterol (Symbicort Turbuhaler—AstraZeneca) as needed was superior to albuterol as needed to prevent asthma exacerbations in patients with mild asthma. The SIENA trial showed that many patients with mild, persistent asthma have a low sputum eosinophil level and do not derive additional benefit from treatments such as mometasone (Asmanex—Merck) or tiotropium (Spiriva—Boehringer Ingelheim).

In the second day of hearings about youth vaping and Juul Labs, a House subcommittee asserted Thursday that the company targeted children and teenagers.

FDA on Wednesday approved glucagon nasal powder (Baqsimi—Eli Lilly). This is the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection. The product is approved to treat severe hypoglycemia in patients with diabetes aged 4 years and older.

The Senate Finance Committee on Tuesday released a bipartisan drug-pricing proposal that would cap older adults' out-of-pocket costs and limit price increases in Medicare. However, the legislation faces opposition from the pharmaceutical industry and conservative groups. The proposal from Committee Chairman Charles E.

FDA announced Monday that it has approved nine applications for the generic versions of pregabalin (Lyrica—Pfizer) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients aged 17 years a

Cities, towns, and counties on Friday filed thousands of documents from corporations across the pharmaceutical supply chain as they laid out a detailed case of how diverse interests fed an opioid epidemic that persisted for nearly 2 decades.

The American Medical Association (AMA) is asking state and federal authorities to step in to help eliminate the current barriers that prevent so many patients with opioid use disorder from receiving appropriate treatment.

Essential oils have soared in popularity. Here is a primer to help you guide your patients in their safe use.

Federal officials said Thursday that Miami-Luken, an Ohio drug wholesale distributor, and two of its former executives have been charged for their roles in the U.S. opioid crisis.